Navigation Links
HPV-Positive Head and Neck Cancers Fare Better
Date:2/12/2008

Patients survive longer, more responsive to treatment than those with HPV-negative tumors

TUESDAY, Feb. 12 (HealthDay News) -- Head and neck cancer patients whose tumors test positive for human papillomavirus (HPV) tend to survive longer and respond better to treatment than those who test negative, a new study says.

HPV, a common virus with strains believed to be responsible for most cervical cancers, has recently been linked to the development of some head and neck cancers, particularly those of the upper throat, or oropharynx.

Researchers followed 96 patients in the late stages of cancer of the oropharynx or larynx (voice box), according to a study published online Feb. 12 in the Journal of the National Cancer Institute. All the patients were enrolled in the same clinical trial and received the same treatment.

Patients with HPV-positive tumors had higher response rates after chemoradiation therapy, compared with patients with HPV-negative tumors (84 percent vs. 57 percent). The two-year overall survival rates of those with HPV-positive tumors were also higher (95 percent vs. 62 percent).

"Our data suggest that the risks and benefits of therapies should be considered separately for HPV-positive and -negative patients," the authors wrote.

More information

To learn more about head and neck cancers, visit the National Cancer Institute.



-- Kevin McKeever



SOURCE: Journal of the National Cancer Institute, news release, Feb. 12, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Study reveals why certain ovarian cancers develop resistance to platinum-based chemotherapy
2. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
3. American Tailgaters Association, ESPNs Sean Salisbury and George Foreman Unite in the Fight Against Pediatric Cancers Around Super Bowl XLII
4. How less can be more when treating some kidney cancers
5. Cell Addiction to Growth Factors May Help Spur Cancers
6. The 2008 Gastrointestinal Cancers Symposium
7. Sperms immune-protection properties could provide link to how cancers spread
8. Survey points out need for education for primary care physicians on rarely seen cancers
9. Obesity, Diabetes Linked to Cancers
10. AMAS Test Measures Lethal Replikin Gene Activity in Lung and Other Cancers
11. Breast MRI spots other cancers, may alter treatment plan
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
HPV-Positive Head and Neck Cancers Fare Better 
(Date:12/8/2016)... , ... December 08, 2016 , ... ... financial consulting services to residential and commercial clients in the northern Alabama and ... for Nobis Works. , Since 1977, Nobis Works has built a network of ...
(Date:12/7/2016)... ... December 07, 2016 , ... Students attending ... the unique opportunity to get hands-on experience in an emergency medical simulation, When ... experience to gain invaluable, real-life medical skills that are critical success in a ...
(Date:12/7/2016)... ... December 07, 2016 , ... Children exposed to secondhand ... at the Icahn School of Medicine at Mount Sinai has found. The study ... young children are exposed to secondhand marijuana smoke, measurable amounts of primary metabolite ...
(Date:12/7/2016)... ... December 07, 2016 , ... OC87 ... with a schizophrenic mother in a unique, personal perspective through animation. , ... trauma and addictive disorders at her private psychotherapy practice. Sheri’s mother, Pearl, lived ...
(Date:12/7/2016)... ... December 07, 2016 , ... It is vital for any ... useful, properly analyzed data. The team at Beckman Coulter has designed Kaluza, templates with ... speed' and the need to operate in a GLP (Good Laboratory Practice) fashion. , ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... -- CANTEL MEDICAL CORP. (NYSE: CMD ) reported ... diluted share, on a 22.1% increase in sales to a ... This compares with net income of $14,254,000, or $0.34 per ... ended October 31, 2015. Non-GAAP net income ... to $21,323,000, or $0.51 per diluted share, compared with non-GAAP ...
(Date:12/8/2016)... 8, 2016   Mederi Therapeutics Inc . has announced regulatory approval by CFDA ... treatment for chronic gastroesophageal reflux disease (GERD). Continue ... ... the Chinese Congress of Digestive Endoscopy, by Professor Jun Liu, Director of Endoscopy at ... , "We are very pleased that Mederi ...
(Date:12/8/2016)... , and SAN DIEGO , Dec. ... services and solutions with cutting edge next-generation sequencing and bioinformatics ... biotechnology company; and the Genome Institute of Singapore ... – a new joint venture between Novogene and AITbiotech – ... Biopolis, Singapore .   The ...
Breaking Medicine Technology: